AROMICS is a Barcelona-based biotechnology company that specialises in functional genomics and proteomics technologies and their application in research and development of new therapies and diagnostic products targeting relevant human health diseases.
OUR MISSION
AROMICS aims to act as a link between basic science and industry, developing novel drugs and molecular diagnostic products that address unmet clinical needs and contribute to the well-being of society.
OUR STRATEGY
AROMICS is centred on the development of innovative products, services and science. Our strategy is focused on identifying, selecting and validating novel molecular biomarkers and applying them to:
Our commercial vision is driven by Biotech upside opportunities based on licensing, milestones and royalty agreements utilizing our IPR and prototypes, complemented by services for securing the growth of the company.
Our staff, composed of highly-qualified and educated professionals (chemists, biochemists, biologist and engineers) with industrial and postdoctoral experience, provides the innovative thinking, R+D+I leadership, commitment and passion necessary to make great research and development happen.
We are convinced that human capital is by far our most valuable asset. That's why we do our utmost to promote continuous education and to provide a stimulating and rewarding environment - not only to attract the best employees but to allow them growing with us.
Narcís Clavell
Chairman of the Board
Carmen Plasencia
Chief Executive Officer
Inmaculada Dalmau
Business Development Assistant
Paula García-Nogales
R&D project Manager
Dr. Nouri Neamati: Professor of Medicinal Chemistry at the University of Michigan College of Pharmacy.
Dr. Albert Abad: Milenium Centre Médic Iradier Unidad de Consejo Y Cuidado Oncológico Milenium Centro Médico Iradier Hospital Sanitas Cima
Dr. Paolo Lombardi, funder and CEO of Naxospharma
AROMICS conducts a number of internal and collaborative R&D projects across a range of therapeutic areas, focused on the identification and validation of molecular biomarkers and their applicability to:
Human diseases such as cancer and viral infectious diseases like HIV or hepatitis, represent the core of our investigation activity. Our current portfolio at therapeutic area, include two leading projects : NAX035 (for malignant mesothelioma treatment) and AB200 (for viral coinfections), both at regulatory preclinics previous to first clinical indications in humans.
In addition to our activity in health-related research, AROMICS also provides analytical solutions for pathogen identification and monitoring to companies working in non-health related industries, such as the agro-food or environmental areas.
Staffed by an experienced scientific and management team, AROMICS offers its partners a fully translational research program focused on:
All of this activity is supplemented by an international network of research collaborators, including private and public research institutions.
